Ro Body ProgramvsWeightWatchers Clinic (Med+)

After an online visit, a licensed provider determines eligibility and can prescribe an FDA-approved GLP-1 such as the Wegovy pen, oral Wegovy, or Zepbound (with compounded options also available). These drugs target gut hormone receptors to reduce appetite and slow digestion. Ro layers on a 12-month coaching curriculum (nutrition, exercise, sleep, habits), monthly provider check-ins, messaging, and lab testing when ordered.

After an online health quiz, a board-certified clinician reviews your history via telehealth and, when appropriate, prescribes an FDA-approved GLP-1 such as semaglutide (Wegovy), tirzepatide (Zepbound), or liraglutide (Saxenda). These drugs mimic gut hormones that slow stomach emptying and curb appetite. WW's app, nutrition counseling, and GLP-1 Success Program run alongside to help you manage diet and side effects through dose titration.

Ro prescribes the GLP-1 medications backed by the strongest evidence: semaglutide produced roughly 15% mean weight loss in STEP 1 and tirzepatide up to about 21% in SURMOUNT-1, with the head-to-head SURMOUNT-5 trial favoring tirzepatide (~20% vs ~14%). Real-world results depend on the medication, dose, and adherence; individual results vary.

The underlying medications are the most effective pharmacotherapy available: in pivotal trials semaglutide 2.4mg produced roughly 15% mean weight loss (STEP 1) and tirzepatide up to about 21% (SURMOUNT-1). WeightWatchers reports members who engage with its GLP-1 Success Program average about 21% body-weight loss at 12 months, though company-reported figures should be read cautiously and individual results vary.

Expect common GI side effects (nausea, vomiting, diarrhea or constipation), most pronounced during dose escalation. Serious but rare risks include pancreatitis and gallbladder disease. Provider check-ins and labs help monitor safety. This is educational information, not medical advice.

GLP-1 therapy commonly causes gastrointestinal effects (nausea, diarrhea, constipation, vomiting) that often ease as the dose is titrated slowly. Rare but serious risks include pancreatitis and gallbladder disease. This is educational information, not medical advice; discuss your history with the clinician.

As of 2026, membership is $39 for the first month, then $149/mo monthly or as low as ~$74/mo with annual prepay. Medication is separate: oral Wegovy from ~$149/mo, Wegovy pen ~$199/mo introductory then up to $349/mo at higher doses, and Zepbound KwikPen cash-pay ~$449/mo. Drug pricing and promos change often.

As of 2026, membership runs $25/mo for the first two months then $74/mo on a 12-month plan. Medication is billed separately and not included; uninsured branded GLP-1 costs can range from roughly $350 to $1,300/mo, so total spend depends heavily on coverage.

Eligibility is determined by a licensed provider after an online visit, generally following GLP-1 prescribing guidelines (typically BMI 30+, or 27+ with a weight-related condition). The program is offered on a cash-pay basis with multiple medication formats.

Candidates complete an online health-history quiz; final suitability is decided in a telehealth consult with a board-certified clinician. GLP-1 prescribing generally follows label criteria (e.g., BMI 30+, or 27+ with a weight-related condition), but the clinician makes the determination.